Health Press Release – Weekly Newsletter for March 1-7, 2011

Stuttering Reigns King at the Oscars

MEMPHIS, Tennessee, February 28, 2011 – Jane Fraser, president, The Stuttering Foundation (www.stutteringhelp.org),
issued the following reaction to the Oscar awards:

"It is an eloquently golden night for people who stutter. The King's
Speech has been a godsend for the entire stuttering community.
"Tom Hooper gave us an inspirational hero, …. Source  : Stuttering Reigns King at the Oscars.

Kuros Treats First Patient With KUR-023, its Novel Dural Sealant Product Candidate

European Study is First Clinical Assessment of Kuros' Proprietary Synthetic Technology

ZURICH, February 28, 2011 – Kuros Biosurgery AG, a biotechnology company focused on the
development of novel biomaterials and bioactive-biomaterial combination
products for trauma, wound and spinal indications, announced today that it
has treated the first patient in a pilot clinical trial investigating the
safety and efficacy of … Read : Kuros Treats First Patient With KUR-023, its Novel Dural Sealant Product Candidate.

Medunik Canada: A Team Strongly Committed to Bringing Novel Orphan Drugs to Canadians With Rare Diseases

A Strategic Turnkey Partnership Opportunity for International Pharmaceuticals

BLAINVILLE, Quebec, February 28, 2011 – ??ric Gervais, Executive Vice-President of Medunik Canada (
medunikcanada.ca/en), is proud to announce the Management Team
(medunikcanada.ca/en/management) of this recently created company.
Medunik Canada is a Quebec pharmaceutical company with 60 employees and one
unique mission – bring novel orphan drugs to Canadians with rare …. Source  : Medunik Canada: A Team Strongly Committed to Bringing Novel Orphan Drugs to Canadians With Rare Diseases.

EXPAT Kiwis Can Support St John Online With Christchurch Earthquake Work

WELLINGTON, New Zealand, February 28, 2011 – Kiwis worldwide can go online to support St John, the ambulance service
provider helping residents and communities in Christchurch after the recent
earthquake which devastated much of the city.

The website www.donatechristchurch.co.nz enables internet and
mobile phone users abroad to make a donation to St John and …. Original article  : EXPAT Kiwis Can Support St John Online With Christchurch Earthquake Work.

Shire Files Complete Response to FDA’s Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema

DUBLIN and LEXINGTON, Massachusetts, February 28, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced that it has submitted a complete
response to the not approvable letter issued by the US Food and Drug
Administration (FDA) to Jerini AG in April 2008 regarding its New Drug
Application for FIRAZYR(R) (icatibant) for the …. Read the original article  : here.

Global Consensus Demands Better Diabetic Foot Health Management

Basic Foot Care for Low-risk Patients is Critical to Reduce Complications
LONDON, February 28, 2011 – A global consensus published this month in Diabetic Medicine aims to help
people with diabetes who are presently at low-risk of foot complications to
undertake a basic foot care regimen in order to reduce their likelihood of
developing serious foot complications in …. Original article on Gaea Times at  : Global Consensus Demands Better Diabetic Foot Health Management.

Santaris Pharma A/S Obtains Exclusive License from Mass General Hospital for Intellectual Property Related to the Regulation of miR-33 for the Treatment of Cardiovascular Disorders

miR-33, an important microRNA that regulates high density lipoprotein (HDL) levels or "good" cholesterol, is a promising therapeutic target for raising good cholesterol levels

HOERSHOLM, Denmark and SAN DIEGO, February 28, 2011 – Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused
on the research and development of mRNA and microRNA targeted therapies,
today announced that …. Source  : Santaris Pharma A/S Obtains Exclusive License from Mass General Hospital for Intellectual Property Related to the Regulation of miR-33 for the Treatment of Cardiovascular Disorders.

Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation

SUNNYVALE, California, February 28, 2011 – Intuity Medical, Inc.(TM), a privately-held company developing innovative
technologies in diabetes management, announced that it has secured a $20M
credit facility from Silicon Valley Bank and Oxford Finance Corporation. The
funds will be used to help complete clinical trials and commercialize
POGO(TM), a fully-integrated blood glucose monitoring system.

Intuity … Original source on Gaea Times at : Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation.

Peripheral Neuropathic Pain Patients in Sweden set to Benefit From First-of-a-Kind Treatment Which Provides Lasting Pain Relief

Decision to Reimburse Qutenza(TM) (capsaicin 8% w/w dermal patch) by Sweden's Dental and Pharmaceutical Benefits Agency (Tand-och Lakemedelsformansverket) Gives new Option to Patients Living With Difficult-to-Treat Condition

STAINES, England, February 28, 2011 – Patients in Sweden living with peripheral neuropathic pain are set to
gain access to a new treatment option which can provide pain relief … Original article on : Peripheral Neuropathic Pain Patients in Sweden set to Benefit From First-of-a-Kind Treatment Which Provides Lasting Pain Relief.

Shire Lends Support to World Rare Disease Day 2011

CAMBRIDGE, Massachusetts and BASINGSTOKE, England, February 28, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced its support of World Rare Disease
Day, joining patients, physicians, and patient organizations around the world
to support a day that focuses attention on rare diseases as a public health
issue and highlights the need for …. Source article on Gaea Times at  : Shire Lends Support to World Rare Disease Day 2011.

Renishaw Diagnostics Enables Customised Multiplex Assays for Precious Research Samples

GLASGOW, Scotland, February 28, 2011 – Renishaw Diagnostics Ltd, a world leading provider of trace
level detection technologies based on the exploitation of surface enhanced
Raman scattering (SERS) and surface enhanced resonance Raman scattering
(SERRS), for research and molecular diagnostics applications, today announced
the launch of its first research use only (RUO) multiplex assay system which
allows precious research …. Source  : Renishaw Diagnostics Enables Customised Multiplex Assays for Precious Research Samples.

Barbados Is Proud of Leading Medical Facility

LONDON, February 28, 2011 – Barbados Fertility Centre is celebrating this week after receiving the
gold seal of approval from Joint Commission International (JCI), who have
reaccredited Barbados Fertility Centre (BFC), meaning the clinic has
maintained the highest standards since the gold seal was first awarded to
them in 2007.

Ann Jacobson, Executive Director at …. Read the original article  : here.

Health Robotics Announces Termination of its Distribution Contract With McKesson Corporation in North America

BOZEN, Sud-Tirol, Italy, February 28, 2011 – Health Robotics today announced that earlier last week, it served proper
notice to McKesson of the immediate termination for cause of their exclusive
CytoCare distribution and services contract in North America, as well as the
termination for cause of their non-exclusive distribution agreement for
i.v.STATION and i.v.SOFT within a subset of …. Original article on Gaea Times at  : Health Robotics Announces Termination of its Distribution Contract With McKesson Corporation in North America.

Chiltern – Spectratox Drug Photoxicity Collaboration Celebrates 25 Years

LONDON, February 28, 2011 – The staffs of Chiltern International Limited (Chiltern), a global
contract research organization (CRO), and Spectratox Limited, celebrate the
25 year mark of their successful collaboration in Drug Phototoxicity.

Chiltern Early Phase and Spectratox have worked together using a
validated and regulatory accepted in vivo human study method for the
assessment … Read the original article on Gaea Times at : Chiltern – Spectratox Drug Photoxicity Collaboration Celebrates 25 Years.

Infinity Group Invests 120 Million RMB in Shijiazhuang Xingbai Pharmaceutical Company Limited, China

SHIJIAZHUANG, China, February 28, 2011 – Infinity Group, an RMB fund pioneer and the leader in cross border China
RMB and dollar private equity funds, announced today that it is investing 120
million RMB ($US18 million) in Shijiazhuang Xingbai Pharmaceutical Company
Limited. Four of Infinity's funds – the SJZ fund, the I-China fund, the
Changzhou fund and the … Original article on : Infinity Group Invests 120 Million RMB in Shijiazhuang Xingbai Pharmaceutical Company Limited, China.

Toxic Sleep: The Silent Epidemic

SKIPTON, England, March 1, 2011 – Grotty old beds could be behind a growing epidemic of 'toxic sleep'.

A new Sleep Council survey* for National Bed Month (March) shows nearly
half of us are getting just six hours sleep or less a night. And an alarming
four out of five people complain of … Read more : Toxic Sleep: The Silent Epidemic.

MajesticMRSS Announces Three Senior Level Appointments

MUMBAI, India, March 1, 2011 – To support the increased demand experienced in its India operations,
MajesticMRSS has announced three senior level appointments. This is another
milestone in its endeavour in establishing new global structure designed to
better support its worldwide clients through timely, consistent, and
integrated Business Intelligence Solutions.

According to Mr. Raj Sharma, … Read : MajesticMRSS Announces Three Senior Level Appointments.

Simbionix Releases Innovative Module for Practicing the Essential Skill of Transseptal Puncturing

CLEVELAND, March 1, 2011 – Simbionix USA Corporation, the world's leading provider of
medical education and simulation technology, is happy to announce the release
of their new Transseptal Puncture Module for the ANGIO Mentor simulator.

Due to the growing interest in catheter ablation of atrial
fibrillation (AF), the transseptal puncture has become a required … Read more >>.

Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs

Through first three cohorts of intravitreal macular degeneration Phase I trial, start of National Eye Institute subconjunctival macular degeneration Phase I trial, publication/submission of cancer studies, presentation at AACR 'Targeting PI3K/mTOR Signaling in Cancer' -

JAMAICA PLAIN, Massachusetts, March 1, 2011 – Paloma Pharmaceuticals, Inc. announced today updates on its age-related
macular degeneration Phase I trials …. Source article on Gaea Times at  : Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs.

Royal Flying Doctor Service Integrates Departments and Improves Prime Resource Utilisation With Quintiq Solution

MELBOURNE, Australia, March 1, 2011 – Quintiq, a leading provider of Advanced Planning and Scheduling
(www.quintiq.com/solutions/advanced-planning-and-scheduling.aspx)
solutions, today announced that the Queensland Section of the Royal Flying
Doctor Service (RFDS) has gone live with a Quintiq multi-resource planning
solution. The integrated rostering solution (
www.quintiq.com/solutions/employee-planning-and-scheduling/rostering-and-shift-scheduling.aspx)
unites assets and personnel planning for the RFDS
Cairns Base, including aircraft, pilots, doctors, nurses, and …. Original source  : Royal Flying Doctor Service Integrates Departments and Improves Prime Resource Utilisation With Quintiq Solution.

Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP

WELLESLEY HILLS, Massachusetts, March 1, 2011 – Source Precision Medicine, Inc., dba SourceMDx ("SourceMDx") has assigned
all its assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn,
Warnke & Gayton, LLP to be liquidated for the benefit of SourceMDx creditors.

Source MDx(R) is an industry leader in developing simple blood …. Original article on Gaea Times at  : Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP.

WISeKey Appoints Dr. Adrienne Corboud Fumagalli, EPFL Vice President for Innovation and Technology Transfer, to its Advisory Committee

GENEVA, March 2, 2011 – WISeKey announced the appointment of Dr. Adrienne Corboud
Fumagalli as a member of its Advisory Committee. The committee, chaired by
Carlos Moreira, WISeKey founder and CEO, provides advice to WISeKey's senior
management regarding matters of strategic business development and future
revenue growth.

Dr. Adrienne Corboud Fumagalli holds the position of …. Original article  : WISeKey Appoints Dr. Adrienne Corboud Fumagalli, EPFL Vice President for Innovation and Technology Transfer, to its Advisory Committee.

Naviscan Announces European Launch of Positron Emission Mammography

European Launch Marked By Presentations of Significant New Clinical Data Demonstrating the Value of PEM in Improving Treatment Decisions for Breast Cancer

VIENNA, March 2, 2011 – Naviscan, Inc., announces the European launch of the Naviscan Positron
Emission Mammography (PEM) scanner at two prestigious radiology conferences
in Vienna. On March 3rd, at the European Society of Breast …. Source  : Gaea News Network.

InspireMD Boosts MGuard Production Capacity

Production Capacity of MGuard, the Unique Thrombus Management Stent System, Will Double in 2011 to Meet Steady Increase in Demand

TEL AVIV, Israel, March 2, 2011 – InspireMD (www.inspire-md.com/site_en/), developer of
the MGuard(TM) net protective stent system (
www.inspire-md.com/site_en/mguard/the-technology/), has expanded its
MGuard production facilities to meet the steady increase in demand. The
driving forces behind the accelerating demand …. Original source  : InspireMD Boosts MGuard Production Capacity.

Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.

VerifyNow System to be used in Drug Developer's Clinical Studies
SAN DIEGO, March 2, 2011 – Accumetrics, Inc., a privately-held developer and marketer of the
VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic
system for measuring platelet reactivity to multiple antiplatelet agents,
announced today that the company has signed an agreement with Portola
Pharmaceuticals, Inc. to develop and … Read more »».

Torchmark Corporation Declares Dividend

MCKINNEY, Texas, March 2, 2011 – Torchmark Corporation (NYSE: TMK) announced that its Board of Directors
has declared a quarterly dividend of $.16 per share on all of the outstanding
common stock of the Company held of record as of the close of business of the
Company's transfer agent on April 1, 2011. The dividend will be … Original article on : Torchmark Corporation Declares Dividend.

Glenmark Generics Receives Final Approval From the U.S. FDA for Levocetirizine Dihydrochloride

This Press Release Supersedes and Replaces the Prior Release.
MUMBAI, India, March 3, 2011 – Glenmark Generics Inc., USA (GGI), the United States subsidiary of
Glenmark Generics Limited (GGL), announced they have been granted final
approval for their Abbreviated New Drug Application (ANDA) from the United
States Food and Drug Administration (U.S. FDA) for Levocetirizine
Dihydrochloride 5 mg tablets, …. Original article  : Glenmark Generics Receives Final Approval From the U.S. FDA for Levocetirizine Dihydrochloride.

European Commission Approves Self-Administration Label for FIRAZYR(R) (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks

DUBLIN and LEXINGTON, Massachusetts, March 3, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced that the European Commission has
approved FIRAZYR for self-administration after training in subcutaneous
injection technique by a healthcare professional. FIRAZYR is the first and
only treatment for acute Type I and Type II hereditary angioedema (HAE)
attacks licensed … Read the original article on Gaea Times at : European Commission Approves Self-Administration Label for FIRAZYR(R) (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks.

SpaFinder Launches UK Wellness Week(TM)

Exclusive Wellness Information and Great Deals on Spa Treatments at https://www.spafinder.co.uk

LONDON, March 3, 2011 – SpaFinder, the world's largest spa and wellness resource and gifting
company, is launching its first ever UK Wellness Week(TM), to be held on the
21-27th March.
With ill health costing employers GBP100 billion in lost employee days
every year[i] …. Original article on Gaea Times at  : SpaFinder Launches UK Wellness Week(TM).

Federal Supply Schedule (FSS) Pricing Added to ProspectoRx From Elsevier / Gold Standard

Addition Creates a More Comprehensive Pricing and Analytics Tool for Pharmaceutical Companies, Pharmacy Benefits Managers and Pharmacy Headquarters

TAMPA, Florida, March 3, 2011 – Elsevier / Gold Standard (www.goldstandard.com/index.html), a
leading developer of drug databases and medication management solutions,
announced today several enhancements to its pricing tool, ProspectoRx (
www.goldstandard.com/pages/ProspectoRx-AboutProspectoRx.html),
including the addition of Federal Supply Schedule (FSS) pricing … Read the original article on Gaea Times at : Federal Supply Schedule (FSS) Pricing Added to ProspectoRx From Elsevier / Gold Standard.

ConvaTec Healthcare Announces Plans to Refinance Secured Term Loans

SKILLMAN, New Jersey, March 3, 2011 – ConvaTec Healthcare, a world-leading developer, manufacturer and marketer
of innovative medical technologies for community and hospital care, today
announced that, recognizing favorable conditions in the credit markets, it is
exploring the option to refinance all or a portion of its senior secured term
loans originally entered into on December 22, 2010.

… Read the original article on Gaea Times at : ConvaTec Healthcare Announces Plans to Refinance Secured Term Loans.

/C O R R E C T I O N – Bristol-Myers Squibb and AstraZeneca/

PARIS and LONDON, March 4, 2011 – In the news release, "ONGLYZA(R) Becomes the First DPP-4 Inhibitor
Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by
Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would
like to advise that the headline was incorrectly transmitted by
PR Newswire and should have read "ONGLYZA(R) Becomes … Original article on : /C O R R E C T I O N — Bristol-Myers Squibb and AstraZeneca/.